The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to ...

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

Paradigm Biopharmaceuticals says the FDA has endorsed key elements of its proposed phase III knee osteoarthritis trial.

clearance from the US Food and Drug Administration (FDA) to offer its MIMneuro software with Centiloid scaling in patients ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Two FDA-approved monoclonal antibody drugs are thought to curb Alzheimer's by reducing levels of protein plaques in the brain New research could turn that theory on its head: The drugs may work by ...

Last week, a congressional report found that FDA's approval of a similar Alzheimer's drug called Aduhelm — also from Biogen and Eisai — was “rife with irregularities,” including a number ...

The team had previously used another drug, SNC80, to achieve similar results in ... Their top candidate was DNP, which has ...